What is RVMD's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 37.84B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for RVMD?

P/E (TTM) is n/a and 52-week range is $47.45 to $224.31 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s RVMD figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for RVMD?

The company profile lists revenue (TTM) near $11M, net income (TTM) near $-30.31B, EPS (TTM) near $-4.80 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Revolution Medicines Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Redwood City, California, US, 212.6M shares outstanding, ISIN US76155X1000 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Free AI scores & summaries library

Revolution Medicines Inc

$RVMD

Health Care · Biotechnology

IR Run Scenarios

$177.96

-5.97%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. The company is headquartered in Redwood City, California and currently employs 883 full-time employees. The company went IPO on 2020-02-13. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).

Employees

883

Website

www.revmed.com/

IPO

2020-02-13

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)